Acrobiosystems Co

Acrobiosystems Co Book Value Growth

The Book Value Growth of Acrobiosystems Co (301080.SZ) as of Oct 20, 2026 is 1.61 %. In the previous year, Book Value Growth was 1.01 % — a change of 59.63% (higher).

Book Value Growth

1.61 %

YoY

59.63%

Last updated:

Book Value Growth of Acrobiosystems Co is 2025 1.61 % . Book Value Growth of Acrobiosystems Co was 2024 1.01 % . It decreases by 59.63% higher compared to the previous year.

The Acrobiosystems Co Book Value Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value Growth
Date
Book Value Growth
Jan 1, 2019
32.85 CNY
Jan 1, 2020
105.67 CNY
Jan 1, 2021
1,131.61 CNY
Jan 1, 2022
3.90 CNY
Jan 1, 2023
1.03 CNY
Jan 1, 2024
1.01 CNY
Jan 1, 2025
1.61 CNY
The Acrobiosystems Co Book Value Growth history
YEARBook Value GrowthYoY
1.61 %+59.63%
1.01 %-1.99%
1.03 %-73.64%
3.90 %-99.66%
1,131.61 %+970.87%
105.67 %+221.72%
32.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Book Value Growth of Acrobiosystems Co is 1.61 % in 2025.

On Eulerpool you can find the complete historical development of Book Value Growth Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Book value growth measures the percentage increase in shareholders' equity. It indicates how effectively the company retains and grows its net assets.

To evaluate Book Value Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Book Value Growth.

Book Value Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Book Value Growth's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co